A phase IB/II trial published by Reiss et al in The Lancet evaluated the safety and antitumor activity of maintenance with PARP inhibition (niraparib) combined with immune checkpoint blockade (nivolumab vs ipilimumab) in patients with advanced pancreatic cancer who had a stable response to platinum-based chemotherapy.
